Medinet Co
2
2M
2
0.08
1
- Areas of investment
Summary
Medinet Co appeared to be the Corporate Investor, which was created in 1995. The main office of represented Corporate Investor is situated in the Kahoku. The venture was found in Asia in Japan.
The top activity for fund was in 2012. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 5 - 10 millions dollars.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Japan. Among the most popular portfolio startups of the fund, we may highlight REGiMMUNE Corporation. Among the most successful fund investment fields, there are Biotechnology, Health Diagnostics.
The typical case for the fund is to invest in rounds with 5 participants. Despite the Medinet Co, startups are often financed by Yasuda Enterprise Development, NIF SMBC Ventures, Japan Asia Investment. The meaningful sponsors for the fund in investment in the same round are Shinkin Capital, SMBC Venture Capital, Japan Asia Investment. In the next rounds fund is usually obtained by SMBC Venture Capital, Nissei Insurance, Nippon Venture Capital.
The current fund was established by Kohji Egawa.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 1
- Rounds per year
- 0.08
- Investments by industry
- Health Diagnostics (1)
- Biopharma (1)
- Biotechnology (1)
- Nursing and Residential Care (1)
- Cloud Security (1)
- Investments by region
-
- Japan (2)
- Peak activity year
- 2008
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 16
- Group Appearance index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| REGiMMUNE Corporation | 01 Feb 2012 | Biotechnology, Health Diagnostics, Biopharma | Late Stage Venture | 5M | Japan, Chiyoda |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.